


Pildralazine

Cat. No.:	HY-106471
CAS No.:	64000-73-3
Molecular Formula:	C ₈ H ₁₅ N ₃ O
Molecular Weight:	197.24
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Pildralazine (Propylidazine) is a hydralazinelike antihypertensive vasodilator containing a free hydrazine group. Pildralazine is orally active, has no significant carcinogenicity in mice model ^{[1][2]} .								
In Vivo	<p>Pildralazine (6-43 mg/kg; p.o.; once daily) shows no significant carcinogenicity in B6C3F1 and BALB/c mice under a long-term bioassay and a transplacental-infantile bioassay^[1].</p> <p>Pildralazine and Hydralazine (HY-B0464A) act on a common receptor, sensitive to endogenous ATP and adenosine in the isolated tail artery from normotensive Wistar (NW) rats^[2].</p> <p>Pildralazine (1 mg/kg; p.o.;) significantly inhibits the onset of severe hypertension in spontaneously hypertensive rats (SHR) model^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male and female B6C3F1 and to female BALB/c mice (8 weeks old)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>100, 200, and 400 ppm dose: 8, 20, and 40 mg/kg/day in B6C3F1 males, 8, 22, and 43 mg/kg/day in B6C3F1 females, and 6, 15, and 34 mg/kg/day in BALB/c females, respectively</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; added in the drinking water; provided for 80 weeks, and observed for 130-133 weeks age</td> </tr> <tr> <td>Result:</td> <td>Resulted over 80% of mice alive beyond 78 weeks of age.</td> </tr> </table>	Animal Model:	Male and female B6C3F1 and to female BALB/c mice (8 weeks old) ^[1]	Dosage:	100, 200, and 400 ppm dose: 8, 20, and 40 mg/kg/day in B6C3F1 males, 8, 22, and 43 mg/kg/day in B6C3F1 females, and 6, 15, and 34 mg/kg/day in BALB/c females, respectively	Administration:	Oral gavage; added in the drinking water; provided for 80 weeks, and observed for 130-133 weeks age	Result:	Resulted over 80% of mice alive beyond 78 weeks of age.
Animal Model:	Male and female B6C3F1 and to female BALB/c mice (8 weeks old) ^[1]								
Dosage:	100, 200, and 400 ppm dose: 8, 20, and 40 mg/kg/day in B6C3F1 males, 8, 22, and 43 mg/kg/day in B6C3F1 females, and 6, 15, and 34 mg/kg/day in BALB/c females, respectively								
Administration:	Oral gavage; added in the drinking water; provided for 80 weeks, and observed for 130-133 weeks age								
Result:	Resulted over 80% of mice alive beyond 78 weeks of age.								

REFERENCES

- [1]. Della Porta G, Dragani TA. Carcinogenicity study in mice on pildralazine, a hydralazinelike antihypertensive compound. J Cancer Res Clin Oncol. 1983;106(2):97-101.
- [2]. Chevillard C, et al. Interactions between hydralazine, propildazine and purines on arterial smooth muscle. Br J Pharmacol. 1981 Aug;73(4):811-7.
- [3]. Dorigotti L, et al. Effects of pildralazine alone and in combination on severe hypertension and cerebrovascular lesions in saline-drinking spontaneously hypertensive rats. Arzneimittelforschung. 1984;34(8):876-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA